Market Eyes LiveRegeneron Pharmaceuticals Inc (REGN) Stock Rating & Analysis
MELANY's data-driven read on Regeneron Pharmaceuticals Inc · Pharmaceutical Preparations.
Regeneron Pharmaceuticals discovers, develops, and commercializes treatments for eye disease, cardiovascular disease, cancer, and inflammation. Its marketed products include low-dose Eylea and Eylea HD for wet age-related macular degeneration and other eye diseases, Dupixent in immunology, Praluent for lowering LDL cholesterol, Libtayo in oncology, Kevzara for rheumatoid arthritis, and Lynozyfic for multiple myeloma. Its largest collaboration partners are Sanofi (Dupixent and others) and Bayer (Eylea).
Why REGN scores 67/100
MELANY scores Regeneron Pharmaceuticals Inc 67/100 by weighing eight factors. Here is how REGN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- P/E 20.5x vs sector 22.0x median
- Forward P/E 13.4x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 44%
Direction and relative strength of the recent share-price trend.
- Price +19.5% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +17%
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for REGN
- Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Regeneron Pharmaceuticals Inc sits in the Biotech (GLP-1 + innovation cluster) theme, which MELANY currently rates 76/100 for strength. Theme strength feeds REGN's momentum and catalyst factors above.
REGN trade plan (members only)
MELANY has a full position plan for Regeneron Pharmaceuticals Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates REGN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Regeneron Pharmaceuticals Inc's 67/100 reflects mature factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about REGN
Is Regeneron Pharmaceuticals Inc (REGN) a buy?
As of 2026-08-21, MELANY rated Regeneron Pharmaceuticals Inc Favorable with a composite score of 67/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Regeneron Pharmaceuticals Inc's MELANY score?
Regeneron Pharmaceuticals Inc (REGN) has a MELANY composite score of 67/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the REGN stock rating calculated?
MELANY scores REGN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Regeneron Pharmaceuticals Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Regeneron Pharmaceuticals Inc (REGN) Favorable with a composite of 67/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the REGN stock price forecast?
MELANY does not publish price targets or forecasts for REGN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 67/100 across eight factors for Regeneron Pharmaceuticals Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is REGN stock overvalued or undervalued?
MELANY's valuation factor currently reads 63/100 for Regeneron Pharmaceuticals Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives REGN's read.
What price should I buy REGN at?
Rather than chasing the current price, MELANY computes a smart entry zone for REGN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying REGN stock?
The top risks MELANY currently flags for Regeneron Pharmaceuticals Inc: Performance partly driven by Biotech (GLP-1 + innovation cluster), rotation away from this theme would hurt; Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Regeneron Pharmaceuticals Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 72/100 for Regeneron Pharmaceuticals Inc, and earnings track record, at 100/100. The 67/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will REGN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 61/100 for REGN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this REGN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores REGN continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
REGN's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.